BridgeMD
New treatment option for Bronchiectasis Adult
Official title Comparison Between Conventional Respiratory Physiotherapy and the Simeox Device in Patients With Bronchiectasis
ClinicalTrials.gov ID: NCT06801327
What this study is testing
- What it's testing
- Physiotherapy is a key treatment for patients with bronchiectasis. An evaluation of the parameters indicative of respiratory health in patients treated with two different respiratory physiotherapy techniques (conventional versus Simeox®) would be very useful in choosing physiotherapy treatments for bronchiectasis patients.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with a diagnosis of bronchiectasis not due to cystic fibrosis who are not hospitalized.
- Age ≥ 18 years.
- Evidence of bronchiectasis in at least one lung lobe from a chest CT scan performed within the 10 years prior to enrollment.
- Absence of exacerbations in the 28 days preceding enrollment.
- Sputum producers with volumes less than or equal to 200 mL/day.
You likely can't join if
- Diagnosis of COPD or bronchial asthma interpreted as primary and predominant diseases compared to bronchiectasis.
- Presence of tracheostomy.
- History of significant hemoptysis (≥300 mL of blood) or requiring embolization or blood transfusions in the 4 weeks preceding enrollment.
- Hemodynamic instability (mean arterial pressure \ 110 bpm).
- Undrained pneumothorax (evident on chest X-ray, deemed not worthy of pleural drainage according to standard clinical-assistance pathways and thus...
- Women who are pregnant or breastfeeding.
See the full eligibility criteria
- Patients with a diagnosis of bronchiectasis not due to cystic fibrosis who are not hospitalized.
- Age ≥ 18 years.
- Evidence of bronchiectasis in at least one lung lobe from a chest CT scan performed within the 10 years prior to enrollment.
- Absence of exacerbations in the 28 days preceding enrollment.
- Sputum producers with volumes less than or equal to 200 mL/day.
- Under treatment with optimized standard therapy for bronchiectasis that has been stable for at least one year, with no changes in the 28 days prior to enrollment.
- Eligible for and/or already undergoing respiratory physiotherapy.
- Signed informed consent.
- Diagnosis of COPD or bronchial asthma interpreted as primary and predominant diseases compared to bronchiectasis.
- Presence of tracheostomy.
- History of significant hemoptysis (≥300 mL of blood) or requiring embolization or blood transfusions in the 4 weeks preceding enrollment.
- Hemodynamic instability (mean arterial pressure \ 110 bpm).
- Undrained pneumothorax (evident on chest X-ray, deemed not worthy of pleural drainage according to standard clinical-assistance pathways and thus subjected to follow-up).
- Women who are pregnant or breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Bologna, Bologna, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bologna, Bologna, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.